HRT Financial sells $2,211 in Profusa (PFSA) shares

HRT Financial LP, a 10% owner and director of Profusa, Inc. (OTC:PFSA), recently reported transactions involving the company’s common stock. On August 11, 2026, HRT Financial sold 2,280 shares of Profusa common stock for a total of $2,211, at a price of $0.97 per share. The firm also acquired 4,016 shares on August 10, 2026, for a total of $3,791, at a price of $0.944 per share.

Following these transactions, HRT Financial LP beneficially owns 111,024 shares of Profusa common stock directly. The transactions come as Profusa’s stock trades near $0.90, down nearly 100% year-to-date. According to InvestingPro analysis, the stock appears slightly undervalued at current levels, with one InvestingPro Tip noting the RSI suggests oversold territory. The platform offers 13 additional exclusive tips for PFSA investors. HRT Financial LP is located in New York, NY.

In other recent news, Profusa Inc. announced that its shareholders have approved several key proposals at the company’s annual meeting. Among these approvals is the planned acquisition of the PanOmics multi-omics diagnostics platform from BioInsights LLC, which marks a significant step forward for the company. Additionally, shareholders authorized a 1-for-25 reverse stock split, which is set to take effect on July 7, 2026. This move is intended to support Nasdaq listing compliance, as detailed in an amendment to the company’s certificate of incorporation filed with Delaware’s Secretary of State.

Furthermore, shareholders elected Lauren Chung as a Class I director to serve until the 2029 annual meeting. Profusa has also submitted a response package to GMED, its European Notified Body, for the regulatory review process of its Lumee Oxygen Platform. This submission follows the completion of quality system and technical documentation assessments. These developments indicate Profusa’s active engagement in both strategic acquisitions and regulatory compliance efforts.